This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- LONDON -- Tricuspid transcatheter edge-to-edge repair (T-TEER) improved how well patients functioned and felt without major cardiovascular events in the first academic randomized trial to affirm the pivotal trial findings.
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. million Americans have moderate to severe tricuspid regurgitation. to receive the device.
“It is going to be an exciting time for JACC: Case Reports to build on a team of multidisciplinary cardiovascular practitioners with diverse backgrounds and experiences, and at different stages of their professional careers, to enhance the journal’s academic and educational impact globally.”
It marks a big step in our goal of delivering point-of-care assisted diagnosis, or POCAD, with unparalleled scalability and accessibility – from the largest academic centers to the most remote rural locations,” added Ehud Raanani, MD, co-founder, AISAP, and director, Leviev Cardiovascular and Thoracic Center, Sheba Medical Center.
“It is going to be an exciting time for JACC: Case Reports to build on a team of multidisciplinary cardiovascular practitioners with diverse backgrounds and experiences, and at different stages of their professional careers, to enhance the journal’s academic and educational impact globally.”
Is there proof for this, or just an academic gossip? On a personal note, we have recorded good E & A Doppler signals across the tricuspid valve, in RHD mitral stenosis, and AF. We know atrial flutters can be confined to one atrium.
Boyangzi Li, Cardiac AA amyloidosis in a patient with obstructive hypertrophic cardiomyopathy, Cardiovascular Pathology, Volume 48, 2020, ) A comment on deep genetic profiling Genetic studies in HOCM are academically exciting.Professionally gratifying. Amyloid -HCM coexistence Medical pathology is never a pure science.It
It is expected in cardiology academic forums, we use the term secondary MR. While secondary MR is preferable, I guess myocardial MR may be a more apt term. That right ventricle is a part of Tricuspid valve apparatus at least to alesser extent. We know secondary MR is further subdivided into ischemic and non-ischemic.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content